Cancer

Add us on Google

Multi-Cancer Blood Test: What It Costs and How to Get One

A multi-cancer blood test needs a clinician order and is rarely covered by insurance. Here is what drives the price, what Galleri and LucenceINSIGHT cost through Mito, and how to get one.

Published

August 27, 2026

Last updated

October 20, 2026

Read time

12 min read

Medically reviewed by

Rhonda Collins, FNP-C

Share

Copy link

Summarize with AI

A multi-cancer early detection (MCED) blood test is a prescription test, so the first thing to know about getting one is that you cannot simply add it to a cart and skip the clinician. A doctor has to order it. The second thing to know is that price varies by test and, for LucenceINSIGHT, by how many cancers the panel screens for, and insurance usually does not cover these tests yet, though HSA and FSA funds often can. This article explains what drives the cost, what the coverage reality actually is, and the practical steps to order one. This article includes Mito’s current prices for Galleri and the three LucenceINSIGHT panels. Check the linked product pages for the latest offers and ordering details.

What is a multi-cancer blood test?

A multi-cancer blood test looks for signals of several cancers at once from a single blood draw. Mito offers two, and both give a “signal to origin” readout: not only whether something looks off, but where to look next.

• Galleri, from GRAIL, reads methylation patterns on cell-free DNA and looks for one cancer signal that GRAIL reports is shared by more than 50 types of cancer. When it finds a signal, it predicts the Cancer Signal Origin ^[1]. It is one fixed test.
• LucenceINSIGHT, from Lucence, uses next-generation sequencing to detect circulating tumor DNA (ctDNA) and cancer-associated viral DNA, then applies machine learning to predict the likely tissue of origin. It comes as three panels of named cancers.

It is important to frame what this is and is not. An MCED test is a screening tool, not a diagnosis. It is an adjunct to guideline-recommended screening such as mammography, colonoscopy, and low-dose CT for eligible smokers. It does not replace them. A negative or low result does not mean you are cancer-free, and a positive result is not a diagnosis. A positive signal calls for a confirmatory clinical workup ordered by your doctor. Galleri and LucenceINSIGHT are prescription-only laboratory-developed tests, and neither has been cleared or approved by the FDA. No major U.S. screening guideline includes MCED testing yet.

For the full explainer on how these tests work and what the evidence shows, see the multi-cancer early detection test guide and the overview of what a multi-cancer early detection test is.

Why screen with a blood test at all?

Cancer is the second leading cause of death worldwide, according to the World Health Organization ^[2]. Yet the majority of cancer deaths in the United States come from cancers that have no recommended screening test at all. Deriving from GLOBOCAN 2024 incidence and mortality data and the list of cancers with a U.S. Preventive Services Task Force ^[3] screening recommendation, over half of US cancer deaths fall outside routine screening programs. Late diagnosis is common: one analysis found that 52.8% of cancers are diagnosed at a late stage, Stage III or IV (Zeng H et al., Lancet 2021). Because five-year survival is generally much higher when cancer is caught early, per NIH National Cancer Institute SEER data ^[4], a blood-based test that widens the net beyond the handful of screenable cancers is the gap MCED is trying to address.

None of this makes MCED a replacement for proven screening. It is an addition for the cancers that current programs miss.

What affects the price of a multi-cancer blood test?

Several real cost drivers sit behind an MCED test, which is why it is priced well above a routine blood panel:

• Advanced sequencing. These tests run deep sequencing to read circulating DNA that may be present at very low levels in the bloodstream: methylation patterns for Galleri, tumor mutations and viral DNA for LucenceINSIGHT. That sequencing depth and the reagents behind it are expensive.
• Machine-learning analysis. Detecting a signal is only half the job. Predicting the likely tissue of origin uses trained machine-learning models, which is a substantial analytic layer on top of the raw sequencing.
• Prescription and telehealth. Because the test is prescription-only, the price reflects a clinician reviewing your eligibility and ordering the test, plus results delivery through a telehealth path. That clinical oversight is part of what you are paying for.
• Panel breadth. The more cancers a panel screens for, the more the analysis has to do. Broader panels generally cost more than a focused one.

The number of cancers a panel targets is the lever most directly tied to price, and it is also the main choice you make with LucenceINSIGHT. Galleri is a single fixed test with one price. See how the options differ below.

Does insurance cover a multi-cancer blood test? What about HSA or FSA?

For most people, insurance does not cover an MCED test today. These are newer, prescription-only laboratory-developed tests, and broad insurance coverage has not caught up to them. Treat an MCED test as an out-of-pocket screening choice unless your specific plan tells you otherwise.

The more useful news is that HSA and FSA funds are often eligible for prescription diagnostic tests, which can make the real cost meaningfully lower on an after-tax basis. Eligibility depends on your plan and the order details, so confirm with your plan administrator.

What do Galleri and LucenceINSIGHT cost through Mito?

Mito members pay Mito’s cost on tests. Membership is $9 per month or $99 per year, and any applicable lab order or draw fee is itemized before you pay. Non-members can order at the non-member price. Both tests are HSA/FSA eligible.

The test price covers the screening test itself. If a test finds a cancer signal, the diagnostic tests that follow, such as imaging or a biopsy, are separate and are not included.

How do you actually get one?

Because an MCED test requires a prescription, the path runs through a clinician rather than a self-serve checkout. With Mito, the flow is built around telehealth so you do not have to source your own doctor’s order:

1. Choose a test on the product page and start the order. For Galleri, you also review GRAIL’s Patient Information Sheet at checkout.
2. Clinician review and order. A clinician reviews your information and, if the test is appropriate for you, places the order. This is also where anyone who is not a fit for the test gets caught. See the eligibility section in the multi-cancer early detection test guide.
3. Blood draw. Galleri is drawn at a Quest Diagnostics location. LucenceINSIGHT is drawn at home. Neither requires fasting.
4. Results through telehealth. Results come back through the telehealth path, and a positive signal is routed to the confirmatory workup your doctor decides on. Galleri results typically arrive about two weeks after the sample reaches GRAIL’s lab, sometimes up to four weeks ^[5]. LucenceINSIGHT’s turnaround is about 25 working days.

If you are a Mito member, an MCED signal does not sit in isolation. It lands alongside your standard bloodwork and the biomarkers Mito already tracks, so the Concierge and your consult can put a result in the context of the rest of your health picture rather than treating it as a one-off report.

Galleri: one broad test

Galleri has one price because it is one fixed test. It looks for a single cancer signal that GRAIL reports is shared by more than 50 types of cancer, many of which have no recommended screening test. You do not choose which cancers it covers. GRAIL recommends it for adults with an elevated risk for cancer, such as those age 50 or older, and not for people who are pregnant, 21 or younger, or undergoing active cancer treatment ^[5]. GRAIL says Galleri can be taken annually. That is the manufacturer’s position, not a guideline recommendation, so if you plan to repeat it, budget for it as a recurring cost and set the interval with your doctor.

LucenceINSIGHT Core, Me, or 12: how coverage scales

LucenceINSIGHT comes in three panels, and price rises with breadth. Lucence positions it for adults 40 and older, or for younger adults with elevated risk. The difference is breadth and personalization, and breadth maps to how much of US cancer mortality the panel’s targeted cancers account for.

• Core screens for signals associated with 6 cancers that together account for more than half of US cancer mortality: thyroid, breast, pancreatic, colorectal, lung, and liver.
• Me is Core plus 1 to 3 more cancers you choose with your doctor from a curated list, for 7 to 9 cancers total, personalized to your family history and personal risk.
• 12 is the comprehensive, gender-specific panel covering 12 cancers, the widest of the three.

The chart below shows how mortality coverage scales with breadth.

How should you decide?

Breadth is not automatically better. A wider test screens for more cancers, but prediction is imperfect, sensitivity varies by cancer and stage, and every result still has to translate into a next step you and your doctor would actually take. The Me panel exists precisely because the useful choice for most people is targeted: keep the highest-mortality cancers in Core, then add the ones your family history and personal risk actually point to.

A reasonable way to decide:

• Start with your risk. The Cancer Risk Profile quiz is a quick way to surface family history and lifestyle factors worth screening for.
• Check eligibility. Galleri is recommended for adults with an elevated risk for cancer, such as those age 50 or older. LucenceINSIGHT’s guidance starts at age 40.
• Match the test to your goal. If you want one broad fixed test, Galleri fits. If you want a focused essential screen, LucenceINSIGHT Core fits. If specific cancers run in your family, Me lets you and your doctor add them. If you want the widest Lucence panel, 12 is the gender-specific comprehensive option.
• Keep your guideline screening. Whatever you choose, mammography, colorectal and cervical screening, lung screening if you qualify, and prostate screening as a shared decision continue ^[3]. MCED supplements them; it does not replace them.
• Plan for the finances. Budget for an out-of-pocket cost, and check whether your HSA or FSA can cover it.

For a step-by-step approach to building screening around your own risk, see the personalized cancer screening plan after 40.

Ready to look at current pricing? For one broad fixed test, see Galleri. For a panel you can personalize, see LucenceINSIGHT Me, or compare LucenceINSIGHT Core and LucenceINSIGHT 12. The side-by-side comparison covers how the two tests differ.

Multi-cancer blood test cost questions

How much does a multi-cancer blood test cost? It is priced well above routine bloodwork because of deep sequencing, machine-learning analysis, and prescription oversight, and the price rises with how many cancers the panel screens for. Through Mito, Galleri costs $636.12 for members at cost and $890.57 for non-members. LucenceINSIGHT member prices range from $430.92 to $1,294.92, while non-member prices range from $603.29 to $1,812.89. Membership is $9 per month or $99 per year, and any lab order or draw fee is itemized before you pay. Prices can vary by state, so check the product pages for current offers.

Does insurance cover it? Usually not today. These are newer prescription-only tests and broad insurance coverage has not caught up. Treat it as an out-of-pocket screening choice unless your plan says otherwise.

Can I use HSA or FSA? Often yes. Prescription diagnostic tests are frequently HSA/FSA eligible, which lowers the after-tax cost. Confirm with your plan administrator.

Do I need a doctor’s order? Yes. MCED tests are prescription-only. Mito provides the lab order through its telehealth path, including the clinician review, so you do not need to arrange your own.

Does the price include follow-up tests? No. If a test finds a cancer signal, the diagnostic tests that follow, such as imaging or a biopsy, are billed separately.

Is a negative result the same as being cancer-free? No. A negative or low result does not rule out cancer, and a positive result is not a diagnosis. MCED complements guideline screening; it does not replace it.

References

1. Blood Test to Detect Cancer Signal Presence. GRAIL (Galleri).
2. Cancer (fact sheet). World Health Organization.
3. Recommendations: Search Results. U.S. Preventive Services Task Force.
4. SEER Cancer Stat Facts. National Cancer Institute.
5. Frequently Asked Questions (FAQs) for Patients. GRAIL (Galleri).

Related reading

• What Is a Multi-Cancer Early Detection (MCED) Test?
• Multi-Cancer Early Detection Test Guide
• Galleri vs. LucenceINSIGHT: MCED Tests Compared
• Personalized Cancer Screening Plan After 40
• Cancer Antigen 125 (CA-125)

Medical disclaimer

This article is for informational purposes only. It does not diagnose cancer, recommend a specific test for you, or replace medical care. Multi-cancer early detection is a screening test, not a diagnosis, and it complements rather than replaces guideline-recommended screening. A negative result does not mean you are cancer-free, and a positive result requires confirmatory evaluation ordered by a qualified clinician who considers your symptoms, history, and risk. Galleri and LucenceINSIGHT are prescription-only laboratory-developed tests, and neither has been cleared or approved by the FDA.